<i>Clk</i> regulates brain ROS levels independently from ARLI. by Alexandra Vaccaro (148308)

Maximum neutralization activity of bnMAbs in a TZM-bl target cell assay. by Laura E. McCoy (386535)

“…<p>(A) The bnMAbs are ordered from left to right according to decreasing medians of MPN. Each point on the graph represents the percent at which the neutralization curve plateaued for a single virus. …”

Overexpression of UHRF1 promotes bladder cancer cell invasion. by Yu Zhang (12946)

miR-UL112-3p inhibits TLR2-dependent activation of IRAK1. by Igor Landais (2213320)

Inhibition of glycolysis inhibits replication of SVA. by Huizi Li (6241586)

STATc is a key regulator of the transcriptional response to hyperosmotic shock-0 by Jianbo Na (12352)

“…After starvation for 4 hours, untreated cells and cells treated for 5 min with 50, 100, 200 and 400 mM sorbitol were fixed with ice cold methanol, and then stained with a monoclonal antibody specific for actin, followed by the incubation with anti-mouse IgG antibody conjugated with Cy5. …”

A model of the risk attributable to flushing from the nest. by Paul A. Smith (373104)

“…<p>The likelihood of a predator observing a bird flush from the nest, and using this cue to find the nest, decreases from 100% at very small flush distances to 0% at very large flush distances. …”

Sequential viral exposure creates an inflammatory host environment. by Yuhao Li (1559569)

Human ApoM overexpression increased MAPK8 mRNA expression in 293T cells. by Lu Zheng (132726)

Examples of the evolutionary simulation that showed hourglass-like developmental correlation. by Takahiro Kohsokabe (18078713)

P1- and P2-mediated delivery of DOX escapes cardiotoxicity associated with free DOX administration. by Sibu P. Kuruvilla (4382191)

“…Further, free DOX mice had a 100% death rate by day 15, while P1- and P2-treated had a 100% survival rate during the monitoring period. …”

Efficacy of MVATG18598 vaccination schedule in the post-exposure BALB/c mouse model. by Stéphane Leung-Theung-Long (830219)

Optimizing the Void Size of Yolk–Shell Bi@Void@C Nanospheres for High-Power-Density Sodium-Ion Batteries by Hai Yang (1646371)

“…The Bi@Void@C-2 shows an excellent rate capacity of 173 mA h g^–1 at ultrahigh current density of 100 A g^–1 and long-cycle life (198 mA h g^–1 at 20 A g^–1 over 10 000 cycles). …”

Optimizing the Void Size of Yolk–Shell Bi@Void@C Nanospheres for High-Power-Density Sodium-Ion Batteries by Hai Yang (1646371)

“…The Bi@Void@C-2 shows an excellent rate capacity of 173 mA h g^–1 at ultrahigh current density of 100 A g^–1 and long-cycle life (198 mA h g^–1 at 20 A g^–1 over 10 000 cycles). …”

Comparison of <i>Killer-Rescue</i> and split <i>ClvR</i> genetics. by Georg Oberhofer (3401438)

MVATG18598 immunization triggers Mtb antigen-specific cells producing IFNγ and induces cells with antigen-specific cytolytic activity. by Stéphane Leung-Theung-Long (830219)

Examination of mitochondrial function and cell viability in <i>PLA2G6</i>-KD cells. by Goichi Beck (818821)

“…(B) Expression levels of CCO are decreased in <i>PLA2G6</i>-KD cells compared with those of SH-SY5Y cells treated with negative control siRNA with statistical significance (*<i>p < 0</i>.…”

Data_Sheet_1_Exploring organizational aspects that promote health-related preventive behavior: using the example of work-related SARS-CoV-2 infection control measures in Germany, A... by Jana Soeder (19779150)

“…A total of 16 items constitute the attitude scores toward oICM (5-point Likert scale). Via mixed-effect model, aspects associated with employees’ attitudes toward oICM were explored. …”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”